Investigation Report on China's Recombinant Human Thrombopoietin Market, 2019-2023


Description
In recent years, the incidence of thrombopenia in China keeps increasing. Thrombopenia is often seen in hematologic diseases such as primary immune thrombopenia, leukemia and aplastic anemia as well as in connective tissue diseases, liver diseases and tumor chemotherapy. Thrombopenia may also be congenital or drug-induced. Primary immune thrombopenia is a clinically common hemorrhagic disease, accounting for 1/3 of hemorrhagic diseases. The annual incidence of primary immune thrombopenia is 5/100,000 to 10/100,000. The number of patients with thrombopenia in China is increasing by over 100,000 every year. Research shows that 20% to 30% of patients receiving chemotherapy have obvious thrombopenia. The incidence of thrombopenia is 81.80% among patients receiving single-agent carboplatin chemotherapy, 58.20% among patients receiving carboplatin combination chemotherapy, 64.40% among patients receiving gemcitabine chemotherapy and 59.30% among patients receiving paclitaxel chemotherapy.
Using thrombopoietin such as Recombinant Human Thrombopoietin is one of the ways to treat thrombopenia. In 2005, Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. (trade name: TPIAO) was approved to be sold in China. By Aug. 2019, it is the only approved Recombinant Human Thrombopoietin product on the Chinese market.
In China, Recombinant Human Thrombopoietin applies to the treatment of patients with thrombopenia (platelet count < 50?109/L) caused by solid tumor chemotherapy when doctors regard it necessary to increase platelet count. It is also used to assist the treatment of patients who have idiopathic thrombocytopenic purpura with platelet count below 20?109/L when glucocorticoids do not work. It is only applied to patients with thrombopenia and patients facing the increasing risk of bleeding. It is not used to increase platelet count to the normal level.
According to CRI's market survey, the sales value of Recombinant Human Thrombopoietin kept rising after the drug was launched in China. In 2017, it reached CNY 523 million, representing a CAGR of 27.90% from 2013 to 2017.
CRI expects that as the number of patients with thrombopenia increases in China, the demand for Recombinant Human Thrombopoietin will also increase. Considering the high growth rate of the Recombinant Human Thrombopoietin market, Recombinant Human Thrombopoietin products by other enterprises will probably be approved to be launched in China in the next few years.
Table of Contents
1 Relevant Concepts of Recombinant Human Thrombopoietin
1.1 Indications for Recombinant Human Thrombopoietin
1.2 Development of Recombinant Human Thrombopoietin in China
1.3 Patents and Government Approval on Recombinant Human Thrombopoietin in China

2 Sales of Recombinant Human Thrombopoietin in China, 2013-2017
2.1 Sales Value of Recombinant Human Thrombopoietin
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Recombinant Human Thrombopoietin
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Recombinant Human Thrombopoietin by Dosage Form in China, 2013-2017
2.3.1 Injections
2.3.2 Development Trend of Dosage Forms

3 Analysis on Major Manufacturer of Recombinant Human Thrombopoietin in China, 2013-2017
3.1 Market Share of Major Manufacturer of Recombinant Human Thrombopoietin
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Shenyang Sunshine Pharmaceutical Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. in China

4 Prices of Recombinant Human Thrombopoietin in China, 2017-2018
4.1 Shenyang Sunshine Pharmaceutical Co., Ltd. (TPIAO)
4.2 Price Trend of Recombinant Human Thrombopoietin

5 Prospect of China's Recombinant Human Thrombopoietin Market, 2019-2023
5.1 Factors Influencing Development of China's Recombinant Human Thrombopoietin Market
5.1.1 Driving Forces and Market Opportunities
5.1.2 Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

Selected Charts
Chart Patents on Recombinant Human Thrombopoietin in China
Chart Government Approval on Recombinant Human Thrombopoietin in China
Chart Sales of Recombinant Human Thrombopoietin in China, 2013-2017
Chart Sales Value of Recombinant Human Thrombopoietin in Parts of China, 2013-2017
Chart Sales Volume of Recombinant Human Thrombopoietin in China, 2013-2017
Chart Sales Volume of Recombinant Human Thrombopoietin in Parts of China, 2013-2017
Chart Sales Value of Recombinant Human Thrombopoietin Injections in China, 2013-2017
Chart Sales Volume of Recombinant Human Thrombopoietin Injections in China, 2013-2017
Chart Market Share of Manufacturer of Recombinant Human Thrombopoietin by Sales Value in China, 2013-2017
Chart Sales Value of Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. in China, 2013-2017
Chart Prices of Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. (TPIAO) in Parts of China, 2017-2018
Chart Forecast on Sales Value of Recombinant Human Thrombopoietin in China, 2019-2023


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

New Pharmaceuticals and Healthcare Reports

Other Reports by China Research and Intelligence

Investigation Report on Chinese Pregabalin Market, 2020-2024

Pregabalin is a new-generation drug for neuralgia treatment. In Jul. 2004, it was approved by the European Union to treat some epileptic seizures in adults. In Dec. 2004, it was approved by the U.S. Food and Drug Administration (FDA) to treat diabeti...

Research Report of Import of Pork in China 2020-2024

According to CRI, with the development of China’s economy and the improvement of living standards, the pork consumption in China is rising. China is the largest pork producer in the world. But pig breeding is costly in China because it is vulnerabl...

Research Report on China's Ship Accessory Equipment Industry 2020-2024

According to CRI, the ship equipment industry is a major part of the comprehensive strength of the shipping industry. The ship equipment manufacturing industry mainly concentrates in coastal areas including Jiangsu, Shanghai, Liaoning, Zhejiang, Shan...

Research Report of Import of Dairy Products Industry in China 2020-2024

According to CRI, with the development of China’s economy and the arise in Chinese people’s living standards, the per capita consumption of dairy products in China keeps rising. Despite the increasing demand for dairy products, the domestic produ...

Research Report of Organ Transplantation in China 2020-2024

According to CRI’s market research, transplantation has become an important way to save the lives of patients with critical diseases such as liver failure and kidney failure. Human organ transplantation in China began to be performed in the 1960s a...

Publisher: China Research and Intelligence